HeartBeam rises after unveiling AI heart‑monitoring partnership
10/03/2026 11:25
** Shares of medical technology firm HeartBeam BEAT.O rise 25% to $1.85 premarket ** Co says it is partnering with Mount Sinai to develop AI tools for at‑home heart monitoring using its cable‑free 12‑lead ECG device ** Says Mount Sinai will provide clinical data and AI expertise to help build and validate the models ** Adds collaboration could expand its reach in preventive cardiology and remote patient care ** Says its device already has FDA clearance for assessing arrhythmia, or irregular heartbeats ** More than 20 patents support the company’s ECG technology - BEAT ** Shares rose ~4% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Heartbeam
See all newsBrief: Heartbeam Announces Strategic Shift To Accelerate Global Adoption Of Its Ambulatory ECG Signal Platform And Leadership Transition
Brief: Heartbeam Reports First Quarter 2026 Results
HeartBeam Q1 net loss narrows as commercialization advances
Brief: Heartbeam Initiates Pilot Study Of First On-Demand 12-Lead ECG Patch To Detect Ischemia Outside The Clinic
Brief: Heartbeam Expands Commercial Presence Across Four Key U.S. Markets With Addition Of Premier Concierge Practice